Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

KEY POINTS

KEY POINTS

  • The US healthcare system is moving from a fee-for-service payment model to one of value-based purchasing, with provisions set forth in legislation for accountable-care organizations, medical homes, bundled payments, and a focus on quality.

  • Value-based payment is a payment method that provides financial incentives to providers who meet certain quality standards in order to foster clinical and financial accountability.

  • Measurement of quality is expanding rapidly throughout the US healthcare system. Quality in healthcare is usually measured through the use of performance indicators, also known as performance measures.

  • It is essential for Medication Therapy Management providers to understand the quality metrics that apply to medication therapy management, which will influence the focus of their practice models.

  • The Medicare Advantage and Medicare Prescription Drug Plan Quality Strategy provide a framework for measuring quality performance for both Medicare Advantage and Medicare Prescription Drug (Medicare Parts C and D) plans. The Centers for Medicare and Medicaid (CMS) measures the quality of Medicare Parts C and D plans with the Star Ratings system.

  • By publicly reporting the ratings, CMS encourages Parts C and D sponsors to improve service quality to attract enrollees to their plans. The measures are also used to determine quality bonus payments (QBPs) for Medicare Advantage (MA) organizations.

  • Medicare Part D ratings include measures for medication use under the domain of patient safety and accuracy of drug pricing. MTM program providers should be mindful of the medication use, safety, and adherence measures as they provide MTM services on behalf of Medicare Part D plans.

  • Starting with the 2016 Star Ratings, CMS has included an MTM-specific quality measure, which evaluates the percentage of MTM-eligible beneficiaries who received a comprehensive medication review. The measure was developed, and is maintained, by the Pharmacy Quality Alliance.

  • CMS intends to adopt further process and outcomes measures for MTM once they are developed and endorsed.

  • Beyond the Star Ratings and quality measures reported by CMS, MTM programs and vendors, like all healthcare providers, should ensure the quality of the services that they provide. Payers should be able to rely on the accuracy, completeness, and appropriateness of patient interactions, written communications to patients and providers, and MTM encounter records.

INTRODUCTION

A Focus on Quality

The 2003 Medicare Modernization Act began to move the United States toward a value-based healthcare system. This was echoed in the Patient Protection and Affordable Care Act (PPACA) of 2009, in which the word value is mentioned at least 214 times.1 The act reforms Medicare payments, with a shift from a fee-for-service model to one of value-based purchasing, with provisions for accountable-care organizations, medical homes, and bundled payments. There is also a focus on quality, exemplified by programs such as the Hospital Value-Based Purchasing Program and updates to the Physician Quality Reporting Program, including financial incentives (Table 4-1).1-3

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.